Research and development Driving scientific innovation to deliver the next generation of transformational medicines and vaccines for patients
Read morePress releases
- ViiV Healthcare presents positive long-term data from phase III study demonstrating efficacy and safety of cabotegravir and rilpivirine, its investigational, long-acting, injectable treatment regimen in adults living with HIV-1
- ViiV Healthcare presents positive 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once-monthly dosing
- ViiV Healthcare and UNC-Chapel Hill announce five-year renewal of innovative HIV cure partnership
Tweets from GSK
-
GSK @GSK
23 years of the GSK IMPACT Awards has given nearly ￡7m to nearly 480 small to medium sized health and wellbeing charities in the UK. We are incredibly proud of this programme. #GSKIMPACTUK #CharityTuesday twitter.com/TheKingsFund/s…
about 20 hours ago
-
GSK @GSK
Congratulations to the winners of this year’s GSK IMPACT Awards. Check out the great work these charities do to improve health and wellbeing in communities across the UK #GSKIMPACTUK
about 22 hours ago -
GSK @GSK
We’re thrilled to win three 2020 REBA Employee Wellbeing awards recognising our commitment to employee health and wellbeing. Best Global or International Wellbeing Strategy, Best Mental Wellbeing Strategy and the Pinnacle Award. Learn more: gsk.to/2xowX3F #EWBAwards20
about 1 day ago
